Additionally, Maksic et al. pointed out that the HLA-DQA1*05 allele plays a significant role in immunogenicity among pediatric IBD patients receiving anti-TNF therapy, particularly infliximab and adalimumab, by increasing the risk of anti-drug antibody formation and loss of therapeutic response. This evidence concerns the gene TNF and inflammatory bowel disease.